- RIUMA Principal
- Listar por autor
Listar por autor "Wilson, Charles"
Mostrando ítems 1-2 de 2
-
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT
Iveson, Timothy; Boyd, Kathleen A; Kerr, Rachel S; Robles-Zurita, José Antonio; Saunders, Mark P; Briggs, Andrew H; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Haydon, Andrew; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; McQueen, John; Pearson, Sarah; Waterston, Ashita; Medley, Louise; Wilson, Charles; Ellis, Richard; Essapen, Sharadah; Dhadda, Amandeep S; Harrison, Mark; Falk, Stephen; Raouf, Sherif; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Farrugia, David; Webb, Andrew; Cunningham, David; Hickish, Tamas; Weaver, Andrew; Gollins, Simon; Wasan, Harpreet; Paul, James[et al.] (NIHR JOURNALS LIBRARY, 2019-12)Background: Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, the regimen is associated with ... -
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
Robles-Zurita, José Antonio; Boyd, Kathleen A.; Briggs, Andrew H.; Iveson, Timothy; Kerr, Rachel; Saunders, Mark P.; Cassidy, Jim; Hollander, Niels Henrik; Tabernero, Josep; Segelov, Eva; Glimelius, Bengt; Harkin, Andrea; Allan, Karen; McQueen, John; Pearson, Sarah; Waterston, Ashita; Medley, Louise; Wilson, Charles; Ellis, Richard; Essapen, Sharadah; Dhadda, Amandeep S.; Hughes, Rob; Falk, Stephen; Raouf, Sherif; Rees, Charlotte; Olesen, Rene K; Propper, David; Bridgewater, John; Azzabi, Ashraf; Farrugia, David; Webb, Andrew; Cunningham, David; Hickish, Tamas; Weaver, Andrew; Gollins, Simon; Wasan, Harpreet S; Paul, James[et al.] (Springer Nature, 2018-11-13)BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus ...